New combo therapy aims to make inoperable bile duct cancer eligible for transplant
NCT ID NCT07471165
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining an immunotherapy drug (PD-L1 inhibitor) with chemotherapy and radiation can shrink advanced bile duct tumors enough to allow a liver transplant. The study will enroll 25 adults with locally advanced perihilar cholangiocarcinoma that cannot be surgically removed. The main goal is to see how many patients successfully complete the treatment and receive a transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-L1 monoclonal antibody (a type of immunotherapy) combined with chemotherapy (gemcitabine, cisplatin, capecitabine) and radiotherapy
- What this could lead to
- If successful, this approach could help more patients with advanced bile duct cancer become eligible for a life-saving liver transplant.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply widely. The combination therapy also carries risks of serious side effects from chemo, radiation, and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PERIHILAR CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinling Hospital of Nanjing University
Nanjing, Jiangsu, 210000, China
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210002, China